Caris Life Sciences, Inc. CAI
Set alert
As of Nov 2, 2:25 PM ET
- YTD
- +20.52%
- 1 year
- +8.10%
- Open
- 34.76
- Prev close
- 34.33
- Mkt cap
- 9.20B
- Vol
- 1.77M
- Avg vol
- 4.85M
- EPS
- 1.69
- P/E
- 19.25
- Div yield
- 0.00%
More statistics
- Low
- 32.18
- High
- 35.05
- Forward P/E
- 91.12
- Beta
- 0.00
- Short ratio
- 2.63
- Inst. own
- 57.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 28.97
- 200-d avg
- 21.54
- 1y target
- 32.46
News
5 days ago zacks.com
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
Caris Life Sciences,?Inc. (CAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
6 days ago benzinga.com
BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.
-
2 weeks ago benzinga.com
Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30
Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and raises the price target from $22 to $30.
2 weeks ago prnewswire.com
Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences®…
-
2 weeks ago benzinga.com
Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
2 weeks ago prnewswire.com
Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
IRVING, Texas, Oct. 15, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading TechBio company, today announced it will report third quarter 2026 financial results on Wednesday, November…
2 weeks ago benzinga.com
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
2 weeks ago prnewswire.com
Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
Eight posters will feature AI-driven approaches to treatment prediction, risk stratification and biomarker discovery advancing precision medicine across multiple cancer types IRVING, Texas, Oct. 14,…
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $36
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.
3 weeks ago defenseworld.net
Caris Life Sciences, Inc. $CAI Shares Newly Bought by City Center Advisors LLC
City Center Advisors LLC acquired a new stake in Caris Life Sciences, Inc. (NASDAQ: CAI) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission.…
3 weeks ago benzinga.com
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
1 month ago investors.com
IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point.
1 month ago seekingalpha.com
Caris Life Sciences: Diagnostics Growth With Room To Run
Caris Life Sciences has an already established profiling business that provides revenue and cash flows for its expanding diagnostics portfolio. CAI reuses molecular data and clinical relationships,…
1 month ago zacks.com
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in…
1 month ago benzinga.com
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
1 month ago prnewswire.com
Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
New partnership highlights the importance of finding cancer earlier through Caris Detect, a multi-cancer early detection blood test now available nationwide IRVING, Texas, Sept. 8, 2026 /PRNewswire/…
2 months ago prnewswire.com
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading…
2 months ago proactiveinvestors.co.uk
Caris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Caris Life Sciences (Nasdaq:CAI), the Nasdaq-listed Techbio company, has published a study describing an artificial intelligence (AI) tool designed to help doctors choose first-line treatment for…
-
2 months ago benzinga.com
Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology'
The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature. In the testing cohort, standard molecular risk patients…
2 months ago prnewswire.com
Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Caris AI Insights for pancreatic cancer is proprietary, only available to Caris Life Sciences customers and not achievable through small panels IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- Caris Life…
2 months ago benzinga.com
Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
2 months ago benzinga.com
Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today
Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in four years.
2 months ago benzinga.com
Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday
Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.
2 months ago seekingalpha.com
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Caris Life Sciences delivered another strong quarter, raising full-year guidance and expanding margins while sustaining positive free cash flow. Accelerating clinical volume growth and the commercial…
-
2 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.
2 months ago seekingalpha.com
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Caris Life Sciences,?Inc. (CAI) Reports Break-Even Earnings for Q2
Caris Life Sciences,?Inc. (CAI) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.54 per share a year ago.
2 months ago marketbeat.com
Caris Life Sciences Q2 Earnings Call Highlights
Caris Life Sciences NASDAQ: CAI reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
-
2 months ago benzinga.com
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est
Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.030 billion-$1.040 billion vs $1.003 billion estimate.
2 months ago prnewswire.com
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests…
3 months ago seekingalpha.com
Caris Life Sciences: Disrupting Cancer Screening And Therapy Selection
Caris Life Sciences is rated a 'Buy' at ~$16.5, with a blended fair value estimate of $22.3, implying ~35% upside, and 23%-26% 2026 estimated revenue growth. CAI's proprietary WES/WTS/WGS technology…
3 months ago prnewswire.com
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August…
-
3 months ago benzinga.com
Caris Life Sciences To Offer In-House PTEN Immunohistochemistry Testing After Recent FDA Approval Of Biomarker-Guided Therapy And Diagnostic Assay
This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic…
3 months ago prnewswire.com
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will…
-
4 months ago benzinga.com
Caris Life Sciences Announces Dual Listing Of Common Shares On NYSE Texas, Effective June 17
Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas…
-
4 months ago benzinga.com
Caris Life Sciences Announces $100M Buyback Plan
Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized…
5 months ago benzinga.com
Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month Lows
A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘s disappointing AI-revenue forecast testing the artificial-intelli
5 months ago benzinga.com
Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech
Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.
-
5 months ago benzinga.com
Caris Life Sciences Announces Publication Of A Caris‑Led Study In The Oncologist The Shows Its Lookback Program's Ability To Identify Previously-Profiled Patients Who Become Eligible For Newly Approved Targeted Therapies
Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with…
-
5 months ago benzinga.com
Citigroup Maintains Buy on Caris Life Sciences, Lowers Price Target to $28
Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $35 to $28.
-
5 months ago benzinga.com
Caris Life Sciences Submits Application To NYSDOH Clinical Laboratory Evaluation Program Seeking Authorization To Perform Caris Assure On Specimens Originating From New York State
Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York…
-
5 months ago benzinga.com
JP Morgan Maintains Overweight on Caris Life Sciences, Lowers Price Target to $30
JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and lowers the price target from $35 to $30.
-
5 months ago benzinga.com
BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Caris Life Sciences Affirms FY2026 Sales Guidance of $1.000B-$1.020B vs $1.007B Est
Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.000 billion-$1.020 billion vs $1.007 billion estimate.
-
5 months ago benzinga.com
Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate
Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst consensus estimate of $210.292 million by 2.80 percent. This is a 78.78 percent increase over…
-
6 months ago benzinga.com
Caris Life Receives MolDX Approval For Caris ChromoSeq
Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that Caris ChromoSeq™ has received MolDX approval, a…
-
6 months ago benzinga.com
Caris Life Sciences Highlights Growing Urgency Of Closing Geographic Gap In Cancer Clinical Trial Access And Role Of RIT Clinical Trial Solution Plays In Bringing Biomarker-Driven Trials To Community Oncology Practices Nationwide
Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations…
6 months ago benzinga.com
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.